The study found that women aged 21-65 years who were due for a Papanicolaou (Pap) test to screen for cervical cancer were about 30% less likely in 2022 to report having received one in the past year compared to 2019. This decline was not observed between 2019 and 2020, during the early part of the pandemic.
The study also found that in 2022, the weighted rates of past-year Pap testing were significantly lower among women living in rural areas compared to urban residents. However, this difference was no longer observed after controlling for sociodemographic factors, including age, race, ethnicity, and insurance status.
The researchers emphasize that cervical cancer is largely preventable through early detection, and the substantial reductions in Pap testing rates could lead to an increase in cervical cancer cases in the coming years. They suggest that healthcare organizations, especially those serving rural communities, should consider expanding access to Pap tests to increase cervical cancer screening rates to pre-pandemic levels.
翻譯成其他語言
從原文內容
www.medscape.com
從以下內容提煉的關鍵洞見
by Joanna 於 www.medscape.com 06-24-2024
https://www.medscape.com/viewarticle/covid-pandemic-may-have-disrupted-cervical-cancer-screenings-2024a1000bnk深入探究